Hybrid pharmacophore design and synthesis of naphthalimide-benzimidazole conjugates as potential anticancer agents

Ahmed Kamal, Pogula Praveen Kumar, Mohammed Naseer Ahmed Khan, Bobburi Naga Sheshadri, Olepu Srinivas

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Naphthalimide-benzimidazole conjugates were prepared using two different types of spacer units; either a simple alkane chain or a substituted piperazine moiety with variable alkyl side chains. Each set of conjugates was evaluated for their in vitro anticancer activity, and compounds 14a, 14b and 20c were found to exhibit significant activity against a number of cancer cell lines. In particular, compound 14a showed remarkable anticancer activity with GI50 values of 0.02 μM and 0.49 μM against central nervous system (SNB-75) and leukemia (K-562) cell lines, respectively. Compound 14b showed noticeable activity against melanoma (MAME-3M) cell line with GI50 value 0.09 μM. Compound 20c also displayed selectivity against leukemia cell lines with GI50 values up to 0.21 μM as well as appreciable broad-spectrum cytotoxicity.

Original languageEnglish (US)
Pages (from-to)374-384
Number of pages11
JournalLetters in Drug Design and Discovery
Volume12
Issue number5
DOIs
StatePublished - Jan 1 2015

Keywords

  • Benzimidazole
  • Conjugates
  • Cytotoxicity
  • Naphthalimide
  • Piperazine

Fingerprint Dive into the research topics of 'Hybrid pharmacophore design and synthesis of naphthalimide-benzimidazole conjugates as potential anticancer agents'. Together they form a unique fingerprint.

  • Cite this